Compared with P, AR (Z: P > 0.99 vs. P: P < 0.0001, ES = 0.85, treatment‐by‐time interaction: P = 0.006), HSD17β3 (Z: P > 0.99 vs. P: P = 0.007, ES = 1.04, treatment‐by‐time interaction: P = 0.02) was blunted after 6 weeks of RET with hypogonadism, with significant differences between two groups (P < 0.05). This evidence concerns the gene HSD17B3 and hypogonadism.